发明名称 |
ANTIBODY GLYCOSYLATION VARIANTS HAVING INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
摘要 |
Provided is the use of a glycoengineered antibody for the preparation of a pharmaceutical composition for the treatment of: i) cancer; ii) autoimmune thrombocytopenia in chronic graft-versus-host disease; or iii) immune-mediated, acquired pure red cell aplasia; wherein said antibody specifically binds the human CD20 antigen, wherein said antibody has a decreased proportion of non-bisected complex oligosaccharides having the m/z value of 1648 Daltons and an increased proportion of bisected hybrid and galactosylated complex oligosaccharides having the m/z values of 1664, 1810, and 1826 Daltons relative to a corresponding, non-glycoengineered anti-CD20 antibody, and wherein said antibody reaches the maximal ADCC activity of Mabthera at an antibody concentration that is approximately five to 10-fold lower as a result of said glycoengineering. |
申请公布号 |
NZ592087(A) |
申请公布日期 |
2012.11.30 |
申请号 |
NZ20020592087 |
申请日期 |
2002.08.05 |
申请人 |
ROCHE GLYCART AG |
发明人 |
BAILEY, JAMES E;UMANA, PABLO;JEAN-MAIRET, JOEL |
分类号 |
C09K5/04;C12N15/09;A61K38/00;A61K39/395;A61P35/00;C07H21/04;C07K16/00;C07K16/18;C07K16/28;C07K16/30;C07K16/42;C07K19/00;C12N5/06;C12N5/10;C12N5/16;C12N5/20;C12N5/24;C12N9/10;C12N15/12;C12N15/13;C12N15/54;C12P21/00;C12P21/06;C12P21/08 |
主分类号 |
C09K5/04 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|